Emmaus Life Sciences Inc (EMMAW) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Emmaus Life Sciences Inc   (EMMAW)

Emmaus Life Sciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Emmaus Life Sciences Inc in the fourth quarter 2025?
Due to the lack of equity, it was not possible to calculate Emmaus Life Sciences Inc 's return on equity (ROE) in its fourth quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - 2626.87 %
Net Income (TTM) in Millions -7 -3 -4 -6 -3
Return On Equity (TTM) - - - - -
EMMAW's Total Ranking # # # # #
Equity (TTM) in Millions -64 -56 -59 -56 -54
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to EMMAW Management Effectiveness >> EMMAW's 5 Years Annual ROE >> Compare EMMAW ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





EMMAW Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -64 -56 -48 -34 -21
Y / Y Equity Change - - - - -
Net Income in Millions -7 -6 -4 -11 -16
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to EMMAW Management Effectiveness >> EMMAW's 5 Years Annual ROE >> Compare EMMAW ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
EMMAW's' Return on Equity at Yahoo Finance
EMMAW's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for EMMAW's Competitors
Subscribers only: Roe for Emmaus Life Sciences Inc 's Suppliers
Subscribers only: Return On Equity for EMMAW's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Dexcom Inc   32.44 %
Phibro Animal Health Corporation  32.06 %
Innoviva Inc   30.60 %
Pro dex Inc   30.23 %
Novartis Ag  30.00 %
Incyte Corporation  29.15 %
Waters Corporation  28.52 %
Puma Biotechnology Inc   27.81 %
Resmed Inc   25.18 %
Encompass Health Corporation  24.76 %
Prestige Consumer Healthcare Inc   24.66 %
Catalyst Pharmaceuticals Inc   24.32 %
Collegium Pharmaceutical Inc   24.11 %
Xoma Royalty Corporation  23.97 %
Chemed Corporation  23.92 %
Iradimed Corporation  23.83 %
Lifevantage Corp  23.04 %
Hims and Hers Health Inc   22.99 %
Vertex Pharmaceuticals Inc  22.70 %
Pacs Group Inc   22.54 %
Spero Therapeutics Inc   22.53 %
Iqvia Holdings Inc   22.05 %
Ge Healthcare Technologies Inc   21.90 %
Msa Safety Inc  21.82 %
Mimedx Group Inc   21.24 %
Universal Health Services Inc   21.19 %
Inspire Medical Systems inc   21.07 %
Astrazeneca Plc  21.00 %
Haemonetics Corporation  20.80 %
Sbc Medical Group Holdings Incorporated  20.79 %

Date modified: 2026-09-08T15:11:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.